Capabilities

Research


 

Research

Our sector specialties include: Consumer; Healthcare; Media; Power & Energy Transition; and Technology. Guggenheim Equity Research analysts average 18 years of Wall Street and industry experience, bringing our clients rich perspectives and deep domain expertise.

Rigorous primary research is central to our approach. Innovation and disruption are constants in the sectors we cover and on-the-ground work keeps our team at the leading edge of trend changes for the benefit of our clients. Our signature research products uncover these findings and include:

  • The Guggenheim 360° series spotlights our analysts' most differentiated work—research that reflects a deep understanding of our covered industries, primary studies using proprietary methods, access to subject matter experts, thought-provoking conclusions, and actionable portfolio ideas.
  • The Guggenheim Data Insights series harnesses alternative data sources to identify changes in fundamental trends in the industries and businesses we cover. With an emphasis on complex and unstructured data sets, our data science team delivers fundamental observations for our analysts to incorporate into their investment opinions.
  • The Grand Rounds series brings to healthcare investors our most important findings from interviews with physicians, scientists, and other leading voices in medicine. Focused on timely debates and key innovations, Grand Rounds surfaces key opinions from primary sources, which are an integral element of our research approach and service to clients.

Meet the teams

Consumer

The Consumer team covers automotive, e-commerce, hardline and softline retail, and restaurants.

View the team

Healthcare

The Healthcare team covers biotechnology, biopharmaceuticals, diagnostics and life sciences tools, and healthcare services.

View the team

Internet & Media

The Internet & Media team covers entertainment, internet, and media.

View the team

Power & Energy Transition

The Power & Energy Transition team covers energy & industrial technology, power, and utilities.

View the team

Technology

The Technology team covers IT services and software.

View the team

For access to our research offerings and products, please contact your Guggenheim Securities Sales representative or email GSInfo@guggenheimpartners.com.

Already Registered? View the content library on the research portal (login required).

360˚, Data Insights, and Grand Rounds summaries


Video highlights


I&I Spotlight Series – Treg-based Therapies

I&I Spotlight Series – Treg-based Therapies

Senior Managing Directors Whitney Wolfe and Yatin Suneja partake in a Q&A session regarding the future of the Treg-Therapies.

Watch video

Highlights From the Second Guggenheim Targeted Protein Day

Highlights From the Second Guggenheim Targeted Protein Day

Senior Managing Director Michael Schmidt discusses the key topics from the event.

Watch video

Conferences


DateSectorLocationConference Name
2/23-2/26HealthcareTellurideHealthy Altitudes Summit
6/23-6/26HealthcareBostonBioFrontier Bus Tour

Social Media Highlights


Wall Street Journal Highlights Michael Morris's Research About Media Consolidation

The Wall Street Journal’s Dan Gallagher highlighted the research of Media & Internet Equity Research Analyst Michael Morris regarding the recent announcement of one of the largest media consolidation transactions of all-time. Morris provided analysis of the deal’s potential implications for shareholders of the world's largest streaming service.

Read More

Biotech Research Analysts Publish Peer-Reviewed Article in Nature Reviews Drug Discovery

Guggenheim Securities Biotechnology Equity Research Analysts Yatin Suneja and Maddalena Delma Caiati, MD PhD are co-authors of the review, “Roads and detours for CAR T cell therapy in autoimmune diseases,” recently published in Nature Reviews Drug Discovery, one of the most influential, high-impact peer-reviewed journals in drug discovery and development.

Read More

Seamus Fernandez Joins CNBC to Discuss the Battle for Market Share in the Weight Loss Drug Industry

Global Biopharmaceutical and Biotechnology Equity Research Analyst Seamus Fernandez recently joined CNBC's "Power Lunch" to discuss his outlook for the two leading companies battling for market share in the weight loss drug industry.

Watch the Video